Table 3. First and second-line treatment.
| Case | 1st line treatment | Localized therapy | 1st radiographic scan result | 1st line PFS | 2nd line treatment | 2nd line treatment radiographic scan | 2nd line PFS | OS |
|---|---|---|---|---|---|---|---|---|
| 1 | Gemcitabine + bevacizumab | None | Progression | 2.4 months | None | N/A | N/A | 4.5 months |
| 2 | Gemcitabine + cisplatin | IMRT given after 1st line therapy | Disease control | 17 months | FOLFIRI | Progression | 3.5 months | 32.8 months |
| 3 | Sorafenib | Stereotactic radiation given after 1st line therapy | Progression | 2.7 months | None | N/A | N/A | 3.3 months |
| 4 | Sorafenib | None | Progression | 6.9 months | Gemcitabine + oxaliplatin + bevacizumab | Disease control | 6.5 months | 14.5 months |
| 5 | Gemcitabine | None | Progression | 3.6 months | None | N/A | N/A | 5.3 months |
| 6 | Gemcitabine + bevacizumab | None | Disease control | 7.3 months | None | N/A | N/A | 8.3 months |
| 7 | Trial with sorafenib | None | Progression | 2.3 months | Gemcitabine + oxaliplatin | Disease control | 8.5 months | 17.5 months |
PFS, progression-free survival; OS, overall survival; IMRT, intensity-modulated radiation therapy.